Barbara Costa

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6031477/publications.pdf

Version: 2024-02-01

95 papers	3,057 citations	136740 32 h-index	182168 51 g-index
95 all docs	95 docs citations	95 times ranked	3925 citing authors

#	Article	IF	Citations
1	Translocator Protein Ligand PIGA1138 Reduces Disease Symptoms and Severity in Experimental Autoimmune Encephalomyelitis Model of Primary Progressive Multiple Sclerosis. Molecular Neurobiology, 2022, 59, 1744-1765.	1.9	3
2	Essential Principles and Recent Progress in the Development of TSPO PET Ligands for Neuroinflammation Imaging. Current Medicinal Chemistry, 2022, 29, 4862-4890.	1.2	9
3	Translocator Protein 18-kDa: a promising target to treat neuroinflammation-related degenerative diseases. Current Medicinal Chemistry, 2022, 29, .	1.2	4
4	Relationship of behavioral inhibition to separation anxiety in a sample (NÂ=Â377) of adult individuals with mood and anxiety disorders. Comprehensive Psychiatry, 2022, 116, 152326.	1.5	1
5	An update into the medicinal chemistry of translocator protein (TSPO) ligands. European Journal of Medicinal Chemistry, 2021, 209, 112924.	2.6	31
6	Carbonic anhydrase activation profile of indole-based derivatives. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 1783-1797.	2.5	3
7	Separation Anxiety and Measures of Suicide Risk Among Patients With Mood and Anxiety Disorders. Journal of Clinical Psychiatry, 2021, 82, .	1.1	14
8	De novo Neurosteroidogenesis in Human Microglia: Involvement of the 18 kDa Translocator Protein. International Journal of Molecular Sciences, 2021, 22, 3115.	1.8	15
9	Synthesis and Screening in Mice of Fluorine-Containing PET Radioligands for TSPO: Discovery of a Promising ¹⁸F-Labeled Ligand. Journal of Medicinal Chemistry, 2021, 64, 16731-16745.	2.9	15
10	18-kDa translocator protein association complexes in the brain: From structure to function. Biochemical Pharmacology, 2020, 177, 114015.	2.0	12
11	Microglial Pro-Inflammatory and Anti-Inflammatory Phenotypes Are Modulated by Translocator Protein Activation. International Journal of Molecular Sciences, 2019, 20, 4467.	1.8	54
12	Unbinding of Translocator Protein 18 kDa (TSPO) Ligands: From in Vitro Residence Time to in Vivo Efficacy via in Silico Simulations. ACS Chemical Neuroscience, 2019, 10, 3805-3814.	1.7	22
13	Translocator protein and steroidogenesis. Biochemical Journal, 2018, 475, 901-904.	1.7	30
14	Oxytocin receptor gene variation, behavioural inhibition, and adult separation anxiety: Role in complicated grief. World Journal of Biological Psychiatry, 2018, 19, 471-479.	1.3	12
15	Bax Activation Blocks Self-Renewal and Induces Apoptosis of Human Glioblastoma Stem Cells. ACS Chemical Neuroscience, 2018, 9, 85-99.	1.7	22
16	Simultaneous Targeting of RGD-Integrins and Dual Murine Double Minute Proteins in Glioblastoma Multiforme. Journal of Medicinal Chemistry, 2018, 61, 4791-4809.	2.9	22
17	Epigenetic Modifications of theÎ±-Synuclein Gene and Relative Protein Content Are Affected by Ageing and Physical Exercise in Blood from Healthy Subjects. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-16.	1.9	16
18	Negative effects of a high tumour necrosis factor-Î± concentration on human gingival mesenchymal stem cell trophism: the use of natural compounds as modulatory agents. Stem Cell Research and Therapy, 2018, 9, 135.	2.4	15

#	Article	IF	Citations
19	Bifunctional Inhibitors as a New Tool To Reduce Cancer Cell Invasion by Impairing MMP-9 Homodimerization. ACS Medicinal Chemistry Letters, 2017, 8, 293-298.	1.3	13
20	Residence Time, a New parameter to Predict Neurosteroidogenic Efficacy of Translocator Protein (TSPO) Ligands: the Case Study of N,Nâ€Dialkylâ€2â€arylindolâ€3â€ylglyoxylamides. ChemMedChem, 2017, 12, 1275-1278.	3.6	9
21	The Anxiolytic Etifoxine Binds to TSPO Ro5-4864 Binding Site with Long Residence Time Showing a High Neurosteroidogenic Activity. ACS Chemical Neuroscience, 2017, 8, 1448-1454.	4.1	33
22	Oxytocin receptor and G-protein polymorphisms in patients with depression and separation anxiety. Journal of Affective Disorders, 2017, 218, 365-373.	3.6	22
23	Exploiting the 4-Phenylquinazoline Scaffold for the Development of High Affinity Fluorescent Probes for the Translocator Protein (TSPO). Journal of Medicinal Chemistry, 2017, 60, 7897-7909.	6.4	13
24	The Citrus Flavanone Naringenin Protects Myocardial Cells against Age-Associated Damage. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-12.	4.9	58
25	TSPO PIGA Ligands Promote Neurosteroidogenesis and Human Astrocyte Well-Being. International Journal of Molecular Sciences, 2016, 17, 1028.	3.2	32
26	Long Residence Time at the Neurosteroidogenic 18 kDa Translocator Protein Characterizes the Anxiolytic Ligand XBD173. ACS Chemical Neuroscience, 2016, 7, 1041-1046.	4.1	13
27	TSPO ligand residence time: a new parameter to predict compound neurosteroidogenic efficacy. Scientific Reports, 2016, 6, 18164.	4.6	53
28	TSPO-ligands prevent oxidative damage and inflammatory response in C6 glioma cells by neurosteroid synthesis. European Journal of Pharmaceutical Sciences, 2016, 88, 124-131.	3.9	36
29	Targeting the 18-kDa translocator protein: recent perspectives for neuroprotection. Biochemical Society Transactions, 2015, 43, 559-565.	2.6	32
30	Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells. Scientific Reports, 2015, 5, 9956.	4.6	77
31	AM251 induces apoptosis and G2/M cell cycle arrest in A375 human melanoma cells. Anti-Cancer Drugs, 2015, 26, 754-762.	2.0	22
32	TSPO ligand residence time influences human glioblastoma multiforme cell death/life balance. Apoptosis: an International Journal on Programmed Cell Death, 2015, 20, 383-398.	3.5	22
33	Analysis of the Antitumor Activity of Clotrimazole on A375 Human Melanoma Cells. Anticancer Research, 2015, 35, 3781-6.	1.5	14
34	Structureâ€“Activity Relationship Refinement and Further Assessment of 4-Phenylquinazoline-2-carboxamide Translocator Protein Ligands as Antiproliferative Agents in Human Glioblastoma Tumors. Journal of Medicinal Chemistry, 2014, 57, 2413-2428.	6.4	41
35	Apoptosis Therapy in Cancer: The First Single-molecule Co-activating p53 and the Translocator Protein in Glioblastoma. Scientific Reports, 2014, 4, 4749.	4.6	62
36	An antibodyâ€free strategy for screening putative HDM2 inhibitors using crude bacterial lysates expressing GSTâ€HDM2 recombinant protein. Drug Testing and Analysis, 2013, 5, 596-601.	3.1	4

#	Article	IF	Citations
37	Toward Highly Potent Cancer Agents by Modulating the C-2 Group of the Arylthioindole Class of Tubulin Polymerization Inhibitors. Journal of Medicinal Chemistry, 2013, 56, 123-149.	2.9	107
38	Human Glioblastoma Multiforme: p53 Reactivation by a Novel MDM2 Inhibitor. PLoS ONE, 2013, 8, e72281.	1.1	67
39	Translocator Protein as a Promising Target for Novel Anxiolytics. Current Topics in Medicinal Chemistry, 2012, 12, 270-285.	1.0	35
40	Synthesis and Biological Evaluation of 4-Phenylquinazoline-2-carboxamides Designed as a Novel Class of Potent Ligands of the Translocator Protein. Journal of Medicinal Chemistry, 2012, 55, 4506-4510.	2.9	36
41	Translocator Protein (TSPO) and Neurosteroids: Implications in Psychiatric Disorders. Current Molecular Medicine, 2012, 12, 426-442.	0.6	39
42	Synthesis of Novel 4-Aryl-1,2,3,4-tetrahydroisoquinolines as Probes for Dopamine Receptor Ligands. Medicinal Chemistry, 2012, 8, 699-704.	0.7	0
43	Anxiolytic properties of a 2-phenylindolglyoxylamide TSPO ligand: Stimulation of in vitro neurosteroid production affecting GABAA receptor activity. Psychoneuroendocrinology, 2011, 36, 463-472.	1.3	40
44	Tertiary amides with a five-membered heteroaromatic ring as new probes for the translocator protein. European Journal of Medicinal Chemistry, 2011, 46, 4506-4520.	2.6	15
45	Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors. European Journal of Medicinal Chemistry, 2011, 46, 2617-2629.	2.6	36
46	Novel imidazoline compounds as partial or full agonists of D2-like dopamine receptors inspired by I2-imidazoline binding sites ligand 2-BFI. Bioorganic and Medicinal Chemistry, 2010, 18, 7085-7091.	1.4	12
47	Reductions in Platelet 18-kDa Translocator Protein Density Are Associated with Adult Separation Anxiety in Patients with Bipolar Disorder. Neuropsychobiology, 2010, 62, 98-103.	0.9	28
48	Inhibition of metalloproteinases derived from tumours: new insights in the treatment of human glioblastoma. Neuroscience, 2010, 168, 514-522.	1.1	49
49	The Spontaneous Ala147Thr Amino Acid Substitution within the Translocator Protein Influences Pregnenolone Production in Lymphomonocytes of Healthy Individuals. Endocrinology, 2009, 150, 5438-5445.	1.4	70
50	Oxytocin receptor polymorphisms and adult attachment style in patients with depression. Psychoneuroendocrinology, 2009, 34, 1506-1514.	1.3	221
51	Identification of Anxiolytic/Nonsedative Agents among Indol-3-ylglyoxylamides Acting as Functionally Selective Agonists at the Î³-Aminobutyric Acid-A (GABA_A) Î±₂ Benzodiazepine Receptor. Journal of Medicinal Chemistry, 2009, 52, 3723-3734.	2.9	27
52	Mutation analysis of oxytocin gene in individuals with adult separation anxiety. Psychiatry Research, 2009, 168, 87-93.	1.7	21
53	Ala147Thr substitution in translocator protein is associated with adult separation anxiety in patients with depression. Psychiatric Genetics, 2009, 19, 110-111.	0.6	56
54	PK 11195 differentially affects cell survival in human wildâ€type and 18 kDa translocator proteinâ€silenced ADF astrocytoma cells. Journal of Cellular Biochemistry, 2008, 105, 712-723.	1.2	33

#	Article	IF	Citations
55	5â€²-Carbamoyl derivatives of 2â€²-C-methyl-purine nucleosides as selective A1 adenosine receptor agonists: Affinity, efficacy, and selectivity for A1 receptor from different species. Bioorganic and Medicinal Chemistry, 2008, 16, 336-353.	1.4	24
56	Anxiolytic-like Effects of N,N-Dialkyl-2-phenylindol-3-ylglyoxylamides by Modulation of Translocator Protein Promoting Neurosteroid Biosynthesis. Journal of Medicinal Chemistry, 2008, 51, 5798-5806.	2.9	80
57	TSPO over-expression increases motility, transmigration and proliferation properties of C6 rat glioma cells. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2008, 1782, 118-125.	1.8	33
58	DPA-714, a New Translocator Proteinâ€“Specific Ligand: Synthesis, Radiofluorination, and Pharmacologic Characterization. Journal of Nuclear Medicine, 2008, 49, 814-822.	2.8	237
59	Benzodiazepine receptor ligands. 8: Synthesis and pharmacological evaluation of new pyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide 3- and 8-disubstituted: High affinity ligands endowed with inverse-agonist pharmacological efficacy. Bioorganic and Medicinal Chemistry, 2006, 14, 758-775.	1.4	33
60	Peripheral Benzodiazepine Receptor: Characterization in Human T-Lymphoma Jurkat Cells. Molecular Pharmacology, 2006, 69, 37-44.	1.0	27
61	2,9-Disubstituted-N6-(arylcarbamoyl)-8-azaadenines as new selective A3 adenosine receptor antagonists: Synthesis, biochemical and molecular modelling studies. Bioorganic and Medicinal Chemistry, 2005, 13, 4679-4693.	1.4	21
62	Insight into 2-phenylpyrazolo[1,5-a]pyrimidin-3-yl acetamides as peripheral benzodiazepine receptor ligands: Synthesis, biological evaluation and 3D-QSAR investigation. Bioorganic and Medicinal Chemistry, 2005, 13, 4821-4834.	1.4	63
63	PIGA (N,N-Di-n-butyl-5-chloro-2-(4-chlorophenyl)indol-3-ylglyoxylamide), a New Mitochondrial Benzodiazepine-Receptor Ligand, Induces Apoptosis in C6 glioma Cells. ChemBioChem, 2005, 6, 1082-1088.	1.3	21
64	A Novel Selective GABAAÎ±1 Receptor Agonist Displaying Sedative and Anxiolytic-like Properties in Rodents. Journal of Medicinal Chemistry, 2005, 48, 6756-6760.	2.9	68
65	High Affinity Central Benzodiazepine Receptor Ligands:Â Synthesis and Biological Evaluation of a Series of Phenyltriazolobenzotriazindione Derivatives. Journal of Medicinal Chemistry, 2005, 48, 2936-2943.	2.9	9
66	Synthesis, Biological Evaluation, and Molecular Modeling of Ribose-Modified Adenosine Analogues as Adenosine Receptor Agonists. Journal of Medicinal Chemistry, 2005, 48, 1550-1562.	2.9	34
67	Preparation and Pharmacological Characterization oftrans-2-Amino-5(6)-fluoro-6(5)-hydroxy-1-phenyl-2,3-dihydro-1H-indenes as D2-like Dopamine Receptor Agonists. Journal of Medicinal Chemistry, 2005, 48, 2646-2654.	2.9	43
68	Peripheral benzodiazepine receptor ligands: mitochondrial transmembrane potential depolarization and apoptosis induction in rat C6 glioma cells. Biochemical Pharmacology, 2004, 68, 125-134.	2.0	87
69	N,N-Dialkyl-2-phenylindol-3-ylglyoxylamides. A New Class of Potent and Selective Ligands at the Peripheral Benzodiazepine Receptor. Journal of Medicinal Chemistry, 2004, 47, 1852-1855.	2.9	75
70	A2A adenosine receptor ligands and proinflammatory cytokines induce PC 12 cell death through apoptosis. Biochemical Pharmacology, 2003, 66, 1953-1962.	2.0	13
71	ETA receptor-mediated Ca2+ mobilisation in H9c2 cardiac cells. Biochemical Pharmacology, 2003, 65, 783-793.	2.0	13
72	New N6- or N(9)-hydroxyalkyl substituted 8-azaadenines or adenines as effective A1 adenosine receptor ligands. European Journal of Medicinal Chemistry, 2003, 38, 801-810.	2.6	9

#	Article	IF	Citations
73	Synthesis and Benzodiazepine Receptor Affinity of Pyrazolo[1,5-a]pyrimidine Derivatives. 3. New 6-(3-Thienyl) Series as Î±1 Selective Ligands. Journal of Medicinal Chemistry, 2003, 46, 310-313.	2.9	36
74	Ribose-Modified Nucleosides as Ligands for Adenosine Receptors:â€‰ Synthesis, Conformational Analysis, and Biological Evaluation of 1â€˜-C-Methyl Adenosine Analogues. Journal of Medicinal Chemistry, 2002, 45, 1196-1202.	2.9	28
75	Benzodiazepine Receptor Ligands. 7. Synthesis and Pharmacological Evaluation of New 3-Esters of the 8-Chloropyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide. 3-(2-Thienylmethoxycarbonyl) Derivative:Â An Anxioselective Agent in Rodents. Journal of Medicinal Chemistry, 2002, 45, 5710-5720.	2.9	22
76	erythro- and threo-2-Hydroxynonyl substituted 2-phenyladenines and 2-phenyl-8-azaadenines: ligands for A1 adenosine receptors and adenosine deaminase. Il Farmaco, 2002, 57, 221-233.	0.9	12
77	Synthesis and preliminary pharmacological evaluation of trans-2-amino-5(6)-chloro-6(5)-hydroxy-1-phenyl-2,3-dihydro-1H-indenes as dopamine receptor ligands. Il Farmaco, 2002, 57, 303-313.	0.9	5
78	Up-regulation of A2A adenosine receptors by proinflammatory cytokines in rat PC12 cells. Biochemical Pharmacology, 2002, 64, 625-631.	2.0	35
79	Synthesis and Benzodiazepine Receptor Binding Activity of 2, 9-Disubstituted Quinolino[2â€², 3â€²-5, 4](3-pyrazolino)[3, 2-b]purin-4-ones. Archiv Der Pharmazie, 2002, 335, 207.	2.1	4
80	Synthesis and Benzodiazepine Receptor Binding Activity of 2,9â€Disubstituted Quinolino[2â€²,3â€²â€5,4](3â€pyrazolino)[3,2â€b]purinâ€4â€ones (VII).. ChemInform, 2002, 33, 169-169.	0.1	0
81	NovelN-(Arylalkyl)indol-3-ylglyoxylylamides Targeted as Ligands of the Benzodiazepine Receptor:Â Synthesis, Biological Evaluation, and Molecular Modeling Analysis of the Structureâ^'Activity Relationshipsâ€. Journal of Medicinal Chemistry, 2001, 44, 2286-2297.	2.9	36
82	2-Arylpyrazolo[1,5-a]pyrimidin-3-yl acetamides. New potent and selective peripheral benzodiazepine receptor ligands. Bioorganic and Medicinal Chemistry, 2001, 9, 2661-2671.	1.4	112
83	Bioisosterism, enantioselectivity, and molecular modeling of new effective N6- and/or N(9)-substituted 2-phenyl adenines and 8-aza analogs: Different binding modes to A1 adenosine receptors. Drug Development Research, 2001, 54, 52-65.	1.4	12
84	Synthesis and preliminary pharmacological evaluation of 5-Hydroxy- and 5,6-dihydroxy-1,2,3,7,12,12a-hexahydrobenzo[5,6]cyclohepta[1,2,3-ij]isoquinoline derivatives as dopamine receptor ligands. Bioorganic and Medicinal Chemistry, 2001, 9, 1447-1458.	1.4	4
85	Regulation of agonist binding to rat ETB receptors by cations and GTPÎ³S11Abbreviations: ETs, endothelins; ETR, endothelin receptors; GTPÎ³S, guanosine 5â€²-O-(2-thiotriphosphate); BQ 788, N-cis-2,6-dimethylpiperidinocarbonyl-l-Î³MeLeu-d-Trp(COOMe)-d-Nle-ONa; IRL 1620, suc-[Glu9, Ala11,15]-endothelin-1 (8-21); and PMSF, phenylmethanesulphonyl fluoride.. Biochemical Pharmacology, 2001, 62, 537-545.	2.0	1
86	c-nucleoside analogues of furanfurin as ligands to a1 adenosine receptors. Bioorganic and Medicinal Chemistry, 2000, 8, 2367-2373.	1.4	13
87	Synthesis and BZR affinity of pyrazolo[1,5- a]pyrimidine derivatives. part 1: study of the structural features for BZR recognition. Bioorganic and Medicinal Chemistry, 1999, 7, 2705-2711.	1.4	28
88	Benzodiazepine receptor ligands. Il Farmaco, 1999, 54, 375-389.	0.9	12
89	Characterization of a cloned Xenopus laevis Serotonin 5-HT1A receptor expressed in the NIH-3T3 cell line. Molecular Brain Research, 1999, 63, 380-383.	2.5	2
90	Benzodiazepine Receptor Ligands. 4. Synthesis and Pharmacological Evaluation of 3-Heteroaryl-8-chloropyrazolo[5,1-c][1,2,4]benzotriazine 5-Oxides. Journal of Medicinal Chemistry, 1999, 42, 2218-2226.	2.9	37

#	Article	IF	Citations
91	Benzodiazepine receptor ligands â€" Part II. Synthesis and biological evaluation of pyrazolo[5,1-c][1,2,4]benzotriazine 4-oxide. European Journal of Medicinal Chemistry, 1998, 33, 237-244.	2.6	10
92	A2a Adenosine receptors: guanine nucleotide derivative regulation in porcine striatal membranes and digitonin soluble fraction. Neurochemistry International, 1998, 33, 121-129.	1.9	4
93	Chemical modification of the dihydropyridines binding sites by lysine reagent, pyridoxal 5â€²-phosphate. Neurochemistry International, 1998, 32, 361-364.	1.9	4
94	2,3-BUTANEDIONE INACTIVATES THE [3 H]NITRENDIPINE BINDING SITES, WHEREAS DIETHYLPYROCARBONATE DOES NOT. Neurochemistry International, 1996, 29, 623-627.	1.9	2
95	Characterization of a voltage-dependent L-type calcium channel from rabbit and turtle brain. Neurochemical Research, 1996, 21, 537-540.	1.6	0